Atriphen dietary supplement (Xymogen brand): Recall - Potential Allergic Reaction Due to Milk and Soy
Audience: Consumer, Health Professional
ISSUE: The nutraceutical company, Xymogen, (Orlando, FL) and FDA, is notifying consumers and health professionals of the recall of Atriphen, a product sold for the support of healthy joint function, because it contains the undeclared allergens, soy and milk.
BACKGROUND: Xymogen learned that Atriphen might contain the two allergens, immediately discontinued sale of the product and had a third-party laboratory test the product to confirm the presence of the allergens.
RECOMMENDATION: People who have an allergy or severe sensitivity to either milk or soy run the risk of serious or life-threatening allergic reaction if they consume this product. Although there have been no reported allergic reactions or any adverse events in connection with the product to date, consumers are urged to return this product for a full refund.
More information is available at www.xymogen.com. Consumers may email pr@xymogen.com for comments or inquiries.
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.